Literature DB >> 8764080

Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1.

Y Quan1, Z Gu, X Li, Z Li, C D Morrow, M A Wainberg.   

Abstract

Kinetic analysis showed that the Ki values and the Ki/Km ratios for mutated, recombinant M184V human immunodeficiency virus type 1 reverse transcriptase (RT) for (-)2'-dideoxy-3'-thiacytidine triphosphate (3TCTP) were 35-fold higher than the equivalent values for wild-type RT but only about twice as high as the equivalent values for each of the triphosphates of ddC (ddCTP) and ddA (ddATP). Fully endogenous RT assays showed that viruses containing the M184V substitution were highly resistant to 3TCTP, with an increase in the 50% inhibitory concentration of 250-fold in comparison with wild-type recombinant virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764080      PMCID: PMC190526     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  23 in total

1.  Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.

Authors:  Z Debyser; A M Vandamme; R Pauwels; M Baba; J Desmyter; E De Clercq
Journal:  J Biol Chem       Date:  1992-06-15       Impact factor: 5.157

2.  Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; S H Hughes
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

3.  A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication.

Authors:  P Charneau; M Alizon; F Clavel
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

4.  Cis elements and trans-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1.

Authors:  J L Darlix; C Gabus; M T Nugeyre; F Clavel; F Barré-Sinoussi
Journal:  J Mol Biol       Date:  1990-12-05       Impact factor: 5.469

5.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.

Authors:  J K Wakefield; S A Jablonski; C D Morrow
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

7.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

8.  Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses.

Authors:  D Trono
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

9.  Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3'-azido-3'-deoxythymidine.

Authors:  S F Lacey; J E Reardon; E S Furfine; T A Kunkel; K Bebenek; K A Eckert; S D Kemp; B A Larder
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

10.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

Authors:  Z Gu; Q Gao; X Li; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  24 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  The importance of the A-rich loop in human immunodeficiency virus type 1 reverse transcription and infectivity.

Authors:  C Liang; X Li; L Rong; P Inouye; Y Quan; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

Review 4.  HIV-1 antiretroviral drug therapy.

Authors:  Eric J Arts; Daria J Hazuda
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

5.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA.

Authors:  J Guo; L E Henderson; J Bess; B Kane; J G Levin
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

7.  Proteomic profiling of HIV-infected T-cells by SWATH mass spectrometry.

Authors:  Jason DeBoer; Melinda S Wojtkiewicz; Nicole Haverland; Yan Li; Emma Harwood; Emily Leshen; Joseph W George; Pawel Ciborowski; Michael Belshan
Journal:  Virology       Date:  2018-03       Impact factor: 3.616

8.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

9.  Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages.

Authors:  Danielle Perez-Bercoff; Sébastien Wurtzer; Séverine Compain; Henri Benech; François Clavel
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

10.  Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.

Authors:  Karidia Diallo; Bruno Marchand; Xin Wei; Luciano Cellai; Matthias Götte; Mark A Wainberg
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.